NORTH CHICAGO, Ill.,
Oct. 29, 2019 /PRNewswire/ -- AbbVie
(NYSE: ABBV), a research-based global biopharmaceutical company,
today announced the launch of Let Me Be Clear, an
empowerment platform for people living with psoriasis. The
initiative, which launches on World Psoriasis Day, invites people
living with psoriasis to share their story, discuss what freedom
from psoriasis would mean to them and access tools to have clear
and informed conversations with their physicians.
"Recent medical advancements have made significant improvements
in reducing the impact of psoriasis for many people; however, far
too many continue to settle for less," said Dominik Hochli, vice
president, global medical affairs, AbbVie. "We are excited to
launch Let Me Be Clear, to help patients recognize
the power of their own voice towards getting the best care
possible."
Impacting more than 125 million people worldwide, psoriasis is a
chronic immune-mediated condition with a significant burden on all
aspects – physical, emotional and psychological – of daily
life.1 Despite the availability of different
management options, many patients remain undertreated or
dissatisfied with their care because their psoriasis is not
adequately controlled.2
People with psoriasis play a central role in their disease
management, including speaking openly and honestly with their
physician about how their care regimen is helping them move towards
a life free from the daily burden of their disease. Let Me Be
Clear provides a platform where people living with psoriasis
can share their experiences and inspire each other not to settle
for a lower quality of life. Additionally, Let Me Be Clear
features actionable information and an interactive guide to help
people with psoriasis understand their disease, learn about their
care options and feel confident discussing goals with their
physician.
"The mission of Let Me Be Clear is personal for me
because I know firsthand the power of sharing your story and being
your own advocate," said Lianne
Hunter, psoriasis patient advocate and Let Me Be
Clear supporter. "My psoriasis used to stop me from doing a lot
of things, including socializing and enjoying life. One of the
biggest ways I was able to overcome that was through connecting
with other people like me. The first time I built up the confidence
to share my story online, I received such a strong, positive
reaction from others living with psoriasis, reaching out to tell me
that I gave them the courage to do the same. It's so important for
people living with psoriasis to have a place where they can share
their experiences and encourage each other, but also have access to
tools that empower them to advocate for the best psoriasis
care."
Visit Let-Me-Be-Clear.com to hear directly from people living
with psoriasis about the full impact of the disease and find
information and tools to help.
About AbbVie
AbbVie is a global, research and development-based
biopharmaceutical company committed to developing innovative
advanced therapies for some of the world's most complex and
critical conditions. The company's mission is to use its expertise,
dedicated people and unique approach to innovation to markedly
improve treatments across four primary therapeutic areas:
immunology, oncology, virology and neuroscience. In more than 75
countries, AbbVie employees are working every day to advance health
solutions for people around the world. For more information about
AbbVie, please visit us at www.abbvie.com. Follow @abbvie on
Twitter, Facebook, LinkedIn or Instagram.
Forward-Looking Statements
Some statements in this news release are, or may be considered,
forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995. The words "believe," "expect,"
"anticipate," "project" and similar expressions, among others,
generally identify forward-looking statements. AbbVie cautions that
these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially
from those indicated in the forward-looking statements. Such risks
and uncertainties include, but are not limited to, competition from
other products, challenges to intellectual property, difficulties
inherent in the research and development process, adverse
litigation or government action, and changes to laws and
regulations applicable to our industry. Additional information
about the economic, competitive, governmental, technological and
other factors that may affect AbbVie's operations is set forth in
Item 1A, "Risk Factors," of AbbVie's 2018 Annual Report on Form
10-K, which has been filed with the Securities and Exchange
Commission. AbbVie undertakes no obligation to release publicly any
revisions to forward-looking statements as a result of subsequent
events or developments, except as required by law.
References:
- International Federation of Psoriasis Associations. Psoriasis
is a serious disease deserving global attention. 2017. Available
at:
https://ifpa-pso.com/wp-content/uploads/2017/01/Brochure-Psoriasis-is-a-serious-disease-deserving-global-attention.pdf.
Accessed October 24, 2019.
- Lebwohl, M, et al. Patient perspectives in the management of
psoriasis: results from the population-based Multinational
Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad
Dermatol. 2014 May;70(5):871-81.e1-30. doi:
10.1016/j.jaad.2013.12.018.
View original
content:http://www.prnewswire.com/news-releases/abbvie-launches-let-me-be-clear-to-empower-people-with-psoriasis-to-speak-up-and-seek-freedom-from-their-disease-300947191.html
SOURCE AbbVie